Since the introduction of the diagnosis-related groups (DRG) system with cost-related and entity-specific flat-rate reimbursements for all in-patients in 2004 in Germany, economics have become an important focus in medical care, including breast centers. Since then, physicians and hospitals have had to gradually take on more and more financial responsibilities for their medical care to avoid losses for their institutions. Due to financial limitations of resources, most medical services have to be adjusted to correlating revenues, which results in the development of a variety of active measures to understand, steer, and optimize costs, resources and related processes for breast cancer treatment. In this review, the challenging task to implement microeconomic management at the clinic level for breast cancer treatment is analyzed from breast cancer-specific publications. The newly developed economic management perspective is identified for different stakeholders in the healthcare system, and successful microeconomic projects and future aspects are described.

Keywords:
Breast cancer, Costs of treatment, Limited resources, Microeconomic solutions, Health economics
1.
Lux MP, Reichelt C, Karnon J, Tänzer TD, Radosavac D, Fasching PA, Beckmann MW, Thiel FC: Cost-benefit analysis of endocrine therapy in the adjuvant setting for postmenopausal patients with hormone receptor-positive breast cancer, based on survival data and future prices for generic drugs in the context of the German health care system. Breast Care 2011;6:381-389.
2.
Beckmann MW, Bader W, Bechtold I, Becker S, Bornhaupt J, Dimpfl T, Friese K, Frobenius W, U. Gembruch U, Grüßner S, Heer IM, Kayser D, Kreienberg R, Petri E, Rimbach S, Scharl A, Schmidt S, Schwenzer T, Solomayer E, et al.: Finanzierung und finanzielle Probleme von Leistungen und Strukturen im Fachgebiet Gynäkologie und Geburtshilfe im Jahr 2011 - allgemeine Aspekte und geburtshilfliche Versorgung. Geburtsh Frauenheilk 2011;71:367-380.
3.
Institut für das Entgeltsystem im Krankenhaus (InEK): DRG Report Browser 2012. www.g-drg.de/ cms/G-DRG-System_2012/Abschlussbericht_zur_Weiterentwicklung_des_G-DRG-Systems_und_Report_Browser/Report-Browser_2010_2012; accessed 14 Dec 2012.
4.
Brown ML, Lipscomb J, Snyder C: The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health 2001;22:91-113.
5.
Barron JJ, Quimbo R, Nikam PT, Amonkar MM: Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat 2008;109:367-377.
6.
Campbell JD, Ramsey SD: The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics 2009;27:199-209.
7.
Allen JM: Economic/societal burden of metastatic breast cancer: a US perspective. Am J Manag Care 2010;16:697-704.
8.
Vera-Llonch M, Weycker D, Glass A, Gao S, Borker R, Qin A, Oster G: Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC Cancer 2011;11:250.
9.
Canadian Breast Cancer Network (CBCN): Breast cancer: economic impact and labour force re-entry. Ottawa, Canada 2010. www.cbcn.ca/documents/Labour_Force_Re-Entry_Report_ENG_CBCN_2010.pdf; accessed 13 Dec 2012.
10.
American Cancer Society (ACS): Cancer Facts and Figures 2012. Atlanta, GA, American Cancer Society, 2012. www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf; accessed 13 Dec 2012.
11.
American Cancer Society (ACS): The Global Economic Cost of Cancer. Atlanta, GA, American Cancer Society, 2010. www.cancer.org/acs/groups/ content/@internationalaffairs/documents/document/acspc-026203.pdf; accessed 13 Dec 2012.
12.
Luengo-Fernandez R, Leal J, Sullivan R: Economic burden of malignant neoplasms in the European Union. Ann Oncol 2012;23(suppl 9):ixe25.
13.
Chirikos TN: Cancer economics: economic impact of the growing population of breast cancer survivors. Cancer Control 2001;8:177-183.
14.
Scitovsky AA, McCall N: Economic impact of breast cancer. Front Radiat Ther Oncol 1978;11:90-101.
15.
Mori A, Goren A, Gilloteau I, Dibonaventura MD: Quantifying the burden of caregiving for patients with cancer in Europe. Ann Oncol 2012;23 (suppl 9):ixe25-6.
16.
Giersiepen K, Heitmann C, Janhsen K, Lange C: Brustkrebs. Gesundheitsberichterstattung des Bun des (GBE), Heft 25. Berlin, Robert Koch-Institut, Mai 2005. www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/Themenhefte/brustkrebs_inhalt.html?nn=2543868; accessed 13 Dec 2012.
17.
Statistisches Bundesamt: Gesundheit. Krankheitskosten 2002. Wiesbaden, 2004.
18.
Gesundheitsberichterstattung des Bundes: Krankheitskosten von Brustkrebs für Deutschland. www.gbe-bund.de; accessed 13 Dec 2012.
19.
Bach PB: Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 2009;360:626-633.
20.
Fischl F, Feiertag A: Wirtschaftsfaktor Brustkrebs - Werden Frauen und ihre Ängste instrumentalisiert? Wien/NewYork, Springer, 2005; ISBN 3-211-23594-9.
21.
Elzawawy A: Breast cancer systemic therapy: the need for more economically sustainable scientific strategies in the world. Breast Care (Basel) 2008;3:434-438.
22.
Anderson BO, Yip CH, Smith RA, Shyyan R, Sener SF, Eniu A, Carlson RW, Azavedo E, Harford J: Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer 2008;113 (8 suppl):2221-2243.
23.
El Saghir NS, Eniu A, Carlson RW, Aziz Z, Vorobiof D, Hortobagyi GN; Breast Health Global Initiative Systemic Therapy Focus Group: Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries. Cancer 2008;113 (8 suppl):2315-2324.
24.
Jacobs VR, Mallmann P: Chief medical clinic manager of a university OB/GYN clinic - an innovative job description as management response for increase of profitability, quality of care, and physicians' freedom of action. Onkologie 2010;33:331-336.
25.
Jacobs VR: Aufgaben und Funktion eines Abrechnungsexperten in einer Frauenklinik. Gynäkologe 2010;43:393-399.
26.
Jacobs VR, Thoedtmann J, Brunner B, Kiechle M: An economic model to reduce the cost of chemotherapy for gynecologic cancer. Int J Fertil Womens Med 2004;49:274-277.
27.
Jacobs VR, Thödtmann J, Brunner B, Kiechle M: Modell eines aktiven Kostenmanagements gynäkoonkologischer Therapien zur Reduktion der Medikamentenkosten um 58.7% innerhalb eines Jahres. Geburtshilfe Frauenheilkd 2005;65:46-55.
28.
Jacobs VR, Thoedtmann J, Euler U, Paepke S, Fischer T, Harbeck N, Kiechle M: Physician-based active cost management of oncological therapies reducing pharmaceutical costs by 83.4% in two years without leaving standard of care. Onkologie 2005;28:441-445.
29.
Braun M, Jacobs VR, Wagenpfeil S, Sattler D, Harbeck N, Nitz U, Bernard R, Kuhn W, Ihbe-Heffinger A: Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer. Onkologie 2009;32:473-481.
30.
Jacobs VR, Mallmann P: Financial quality control of in-patient chemotherapy in Germany: are additional payments cost-covering for pharmaco-oncological expenses? Breast Care (Basel) 2011;6:120-125.
31.
Jacobs VR: Making or losing money with participation in clinical trials: a decision analysis. Onkologie 2009;32:411-416.
32.
Jacobs VR: Current status of financing and reimbursement of herceptin (Trastuzumab) for adjuvant and advanced therapy of breast cancer in Germany. Breast Care 2006;1:86-94.
33.
Jacobs VR, Rasche L, Harbeck N, Warm M, Mallmann P: Underfinancing of 90.3% for implant costs of prostheses and expanders in DRG-revenues for uni- and bilateral mastectomy with immediate breast reconstruction. Onkologie 2010;33:584-588.
34.
Ihbe-Heffinger A, Paessens BJ, von Schilling C, Shlaen M, Gottschalk N, Berger K, Bernard R, Kiechle M, Peschel C, Jacobs VR: Management of febrile neutropenia - a German prospective hospital cost analysis in lymphoproliferativ disorders, non-small cell lung cancer, and primary breast cancer. Onkologie 2011;34:241-246.
35.
Jacobs VR, Mayer SC, Paessens BJ, Bernard R, Harbeck N, Kiechle M, Ihbe-Heffinger A: Comparison of hospital costs vs. DRG revenues for in-patient treatment of febrile neutropenia during adjuvant anthracycline ± taxane-based CTX for primary breast cancer. Onkologie 2011;34:614-618.
36.
Jacobs VR, Augustin D, Wischnik A, Kiechle M, Hoess C, Steinkohl O, Rack B, Kapitza T, Krase P: CTX and CTX-related direct medication costs saved by testing biomarkers uPA and PAI-1 in primary breast cancer: results of a prospective multi-center study at Certified Breast Centers in Germany. Cancer Res 2012;72(24 suppl):S457.
37.
Jacobs VR, Mallmann P: Finanzielle Qualitätssicherung durch Ressourcenmanagement ‘von innen' durch Ärzte: Sechs ökonomisch erfolgreiche Projekte an der Uniklinik Köln und ihr Einsparungspotential. Arch Gynecol Obstet 2012; 286(suppl 1):S138.
38.
Rasche L, Jacobs VR: Prophylactic bilateral mastectomy in BRCA-1 and BRCA-2: unreasonable difference of 1,534.22 € in reimbursement for similar operations with same costs and effort. Arch Gynecol Obstet 2010;282(suppl):S234-235.
39.
Jacobs VR, Augustin D, Wischnik A, Kiechle M, Hoess C, Steinkohl O, Rack B, Kapitza T, Krase P: Analysis of test-therapy concordance for biomarkers uPA and PAI-1 in primary breast cancer in clinical hospital routine: results of a prospective multi-center study at Certified Breast Cancers in Germany. Cancer Res 2012;72(24 suppl):S455-456.
40.
Choosing Wisely. www.abimfoundation.org/Initiatives/Choosing-Wisely.aspx; accessed on 12 Dec 2012.
41.
Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, Wollins DS: American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012;30:1715-1724.
42.
Beckmann, MW, Bader W, Bechtold I, Becker S, Bornhaupt J, Dimpfl T, Friese K, Frobenius W, Gembruch U, Grüßner S, Heer IM, Kayser D, Kreienberg R, Petri E, Rimbach S, Scharl A, Schmidt S, Schwenzer T, Solomayer E, Steiner E, Strauss A, Vetter K, Wallwiener D, Lux MP: Finanzierung und finanzielle Probleme von Leistungen und Strukturen im Fachgebiet Gynäkologie und Geburtshilfe im Jahr 2011 - DRG-System und stationäre Versorgung inklusive Urogynäkologie und benigner wie auch maligner gynäkologischer Operationen. Geburtsh Frauenheilk 2011;71:497-510.
43.
Beckmann WM, Kaufmann M: Ist die Versorgung von Patientinnen mit Mammakarzinom im derzeitigen Vergütungssystem finanzierbar - Wird Qualität auch bezahlt in Brustzentren? Geburtsh Frauenheilk 2007;67:957-958.
44.
Beckmann MW, Bani MR, Loehberg CR, Hildebrandt T, Schrauder MG, Wagner S, Fasching PA, Lux MP: Are certified breast centers cost-effective? Breast Care (Basel) 2009;4:245-250.
45.
Beckmann MW, Bechtold I, Debus G, Feige A, Frobenius W, Kiesel L, Kunzmann U, Lux M, Sehouli J, Solomayer E, Steiner E, Wagner S: Ist die zukünftige Finanzierung von medizinischer Qualität noch gesichert? Bericht der Finanzierungskommission der DGGG e.V. - Teil I. Geburtsh Frauenheilk 2008;68:1204-1214.
46.
Beckmann MW, Bechtold I, Debus G, Feige A, Frobenius W, Kiesel L, Kunzmann U, Lux MP, Sehouli J, Solomayer E, Steiner E, Wagner S, Schwenzer T, Kreienberg R, Wallwiener D: Ist die zukünftige Finanzierung von medizinischer Qualität noch gesichert? Bericht der Finanzierungskommission der DGGG e.V. - Teil II. Geburtsh Frauenheilk 2009;69:56-65.
47.
Thiel FC, Scharl A, Hildebrandt T, Kotziabassis E, Schrauder MG, Bani MR, Müller A, Hauzenberger T, Loehberg CR, Jud SM, Fasching PA, Hartmann A, Schulz-Wendtland R, Strnad V, Beckmann MW, Lux MP: Financing of certified centers: a willingness-to-pay analysis. Arch Gynecol Obstet 2012;Epub ahead of print.
48.
Jacobs VR, Mayer SC, Paessens BJ, Bernard R, Harbeck N, Kiechle M, Ihbe-Heffinger A: Comparison of actual hospital costs versus DRG revenues for in-patient treatment of febrile neutropenia during adjuvant anthracycline plus/minus taxane-based chemotherapy for primary breast cancer. Onkologie 2011;34:614-618.
49.
Sozialgesetzbuch SGB V. www.gesetze-im-internet. de/sgb_5/__275.html; accessed on 17 Dec 2012.
50.
Böhmann D: Bonuszahlungen für Fallzahlen? Wider die ökonomischen Determinanten ärztlichen Handelns; in Forschung und Lehre 2012, pp. 992-993. www.forschung-und-lehre.de.
51.
OnkoZert. www.onkozert.de/brustkrebszentren.htm; accessed on 12 Dec 2012.
52.
European Society of Breast Cancer Specialists (EUSOMA). www.eusoma.org; accessed on 12 Dec 2012.
53.
OnkoZert. www.onkozert.de/brustkrebszentren/karte.htm; accessed on 12 Dec 2012.
54.
Institut für das Entgeltsystem im Krankenhaus (InEK): Anfrage zur differenzierten Auswertung der InEK-Kalkulationsdaten nach Strukturqualität. Reply letter to DRG Commission at Bundesärztekammer Berlin (BAEK) from 21.01.2010.
55.
Scheller-Kreinsen D, Euro DRG Group: How well do diagnosis-related group systems group breast cancer surgery patients? Evidence from 10 European countries. Health Econ 2012;21(suppl 2):41-54.
56.
Hoffmann J, Wallwiener D: Breast cancer surgery and financial reimbursement in Germany. Breast Care 2012;7:384-388.
57.
Lotter O, Amr A, Jaminet P, Hoefert S, Schaller HE, Stahl S: (Development of DRGs in reconstructive breast surgery). Handchir Mikrochir Plast Chir. 2012;44:112-117.
58.
Kuhrt N: Was darf ein Monat Leben kosten? Frankfurter Allgemeine Zeitung (FAZ) 20.01.2010. www.faz.net/aktuell/wissen/medizin/krebstherapie-was-darf-ein-monat-leben-kosten-1907448.html; accessed on 12 Dec 2012.
59.
Colla CH, Morden NE, Skinner JS, Hoverman JR, Meara E: Impact of payment reform on chemotherapy at the end of life. Am J Manag Care 2012;18:e200-8.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.